Institutional Ownership Data

Biotech Specialist Hedge Fund Positions

Cleaned and structured 13D/13G ownership disclosures and 13F institutional holdings for biotech-focused funds. New positions, stake reductions, and activist crossings, linked to company and trial identifiers.

Request dataset →

Live Sample

What the data looks like

Live data from our pipeline.

Nurix Therapeutics, Inc. NRIX Sep 23

Perceptive Advisors

5.3% New position SC 13G
Tyra Biosciences, Inc. TYRA Sep 21

BVF Partners L.P.

6.1% ↑2.1% SC 13G
CalciMedica, Inc. CALC Aug 25

Stonepine Capital Management, LLC

6.0% ↑1.4% SC 13G
Skye Bioscience, Inc. SKYE Sep 24

5AM Ventures

26.1% ↓4.1% SC 13D/A
Oruka Therapeutics, Inc. ORKA Aug 14

RTW INVESTMENTS, LP

5.2% ↑0.9% SC 13G

Live data from our pipeline. The structured export includes all fields listed below.

Use Cases

Who Uses This Data

Structured for direct analysis. No data cleaning, no manual joins required.

Investors and Quantitative Analysts

  • ● Track when biotech-focused funds cross ownership thresholds or change ownership intent (13D)
  • ● Screen for multi-fund convergence on the same company as a conviction indicator
  • ● Export clean historical position data for quantitative models without manual EDGAR parsing
  • ● Cross-reference fund moves with trial events and 8-K signals in your own system

Investor Relations and Corporate Strategy

  • ● Identify specialists active in your therapeutic area
  • ● Track peer company institutional ownership trends for competitive IR positioning
  • ● Prepare for shareholder conversations with current and historical ownership structure data

What's Included

Data Fields

Primary Sources

  • • SEC EDGAR Schedule 13D and 13G filings
  • • SEC EDGAR Form 13F institutional holdings
  • • 500+ tracked public biotech companies with CIK, ticker, CUSIP

Fields Include

  • • Fund name and SEC CIK
  • • Company name, ticker, CIK, and CUSIP
  • • Filing type (13D active, 13G passive, 13F holdings)
  • • Filing date and period of report
  • • Shares held and ownership percentage
  • • Change type (new position, increase, decrease, exit)
  • • Change percentage versus prior period
  • • Activist vs. passive distinction (13D vs. 13G)
  • • Linked trial count and therapeutic area per company

Get the Data

or email [email protected]